Publication Bias in Antipsychotic Trials

By
-
0
321

Researchers in Oregon looked for discrepancies between published and unpublished FDA-registered trials. They found that four of the 24 FDA-registered trials of second-generation antipsychotics identified were unpublished. The mean effect size of the published trials was approximately double that of the unpublished trials. Results appeared this week in PLoS Medicine.

 Article →

Related articles:
Washington Post
Medscape
Sydney Morning Herald
Fox News
Psych Central
ABC News

***

Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.

Previous articleMindfulness Decreases Depression & Anxiety, Increases Hope
Next articlePharmaceutical Trial Database Mysteriously Disappears
Kermit Cole
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].

LEAVE A REPLY